Kisspeptin-10 (KSPTN)
OtherClinical (investigational)Also known as: KSPTN peptide, Novel research peptide
KSPTN is the vendor shorthand for kisspeptin, a naturally occurring peptide encoded by the KISS1 gene and the master upstream regulator of the reproductive (hypothalamic-pituitary-gonadal) hormone axis. The research material sold under this code is typically kisspeptin-10, the active decapeptide fragment (YNWNSFGLRF-NH2, also called metastin 45-54) that stimulates GnRH release and, downstream, LH, FSH and the sex hormones.
Overview
At A Glance
Kisspeptin is the peptide product of the KISS1 gene and the endogenous ligand for the receptor KISS1R (formerly GPR54). The material sold as KSPTN is typically kisspeptin-10, the C-terminal decapeptide (YNWNSFGLRF-NH2, metastin 45-54) that retains full receptor activity; the pare…
Overview
KSPTN is the vendor shorthand for kisspeptin, a naturally occurring peptide encoded by the KISS1 gene and the master upstream regulator of the reproductive (hypothalamic-pituitary-gonadal) hormone axis. The research material sold under this code is typically kisspeptin-10, the active decapeptide fragment (YNWNSFGLRF-NH2, also called metastin 45-54) that stimulates GnRH release and, downstream, LH, FSH and the sex hormones. Unlike testosterone or hCG, kisspeptin acts at the very top of the axis and recruits the body's own GnRH pulse generator. It has been studied in human clinical trials for IVF egg-maturation triggering, hypogonadism, hypothalamic amenorrhea and sexual desire, but it is not an approved drug and is sold strictly for research use only (RUO).
What to Expect
- •In research settings a single intravenous dose raises LH within minutes, peaking early and fading quickly because the peptide clears in minutes [PMID:17323132]
- •In men that LH rise can be followed by a modest, transient testosterone increase that is larger in younger men and weaker with age [PMID:30590872]
- •Hormone levels tend to stay within a physiological range rather than spiking to supraphysiologic levels, because the effect works through the body's own axis
- •The response is self-limiting: continuous or repeated high dosing desensitizes the receptor and reduces the effect instead of compounding it
- •No validated response has been characterized for subcutaneous self-administration of kisspeptin-10; any such outcomes are anecdotal rather than clinical
Individual responses vary. Timeline based on commonly reported research observations.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
1302.5 g/mol (kisspeptin-10; molecular formula C63H83N17O14; CAS 374675-21-5)
Amino Acid Sequence
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Research use only; not for human consumption. Kisspeptin directly stimulates the reproductive hormone axis, so it should not be used by anyone pregnant, breastfeeding, or trying to conceive outside medical supervision, nor by anyone with hormone-sensitive conditions (for example certain reproductive cancers) without specialist oversight. Its action on the HPG axis makes it inappropriate for minors. Anyone on hormonal therapy, fertility treatment, or with pituitary or reproductive disorders should not use it outside a controlled clinical setting. No validated dosing exists for self-administration.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$29.00
up to $39.00
$3.9000
1
2
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
KSPTN 5mg | vial | 1 vial● In Stock | $29.00BEST | $5.800 | — | |
|
|
KSPTN 10mg | vial | 1 vial● In Stock | $39.00VALUE | $3.900 | — |
Tracking since Apr 22, 2026 · 2 data points
Vendors Selling Kisspeptin-10 (KSPTN)
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllAminotadalafil
OtherPreclinicalAminotadalafil is an unapproved research analog of tadalafil, the PDE5 inhibitor marketed under the brand name Cialis for erectile dysfunction and under Adcirca for pulmonary arterial hypertension.
B7-33
OtherPreclinicalB7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.
Melanotan I
OtherFDA ApprovedMelanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7.
PNC-27
OtherPreclinicalPNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells.
Prostamax
OtherPreclinicalProstamax is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St.
RU-58841
OtherPreclinicalRU-58841 (also known as PSK-3841 or HMR-3841, and commonly written simply as RU in hair-loss forums) is a non-steroidal androgen receptor antagonist originally developed by Roussel Uclaf (later absorbed into Sanofi) in the late 1980s and early 1990s.
View Full Dosage Guide →
Protocols, calculator & safety for Kisspeptin-10 (KSPTN)
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
75%Quick Facts
Half-Life
Kisspeptin-10: very short, reported on the order of ~4 minutes (rapid plasma clearance). Kisspeptin-54 is longer-acting (tens of minutes). The brief half-life is why human studies dose it intravenously by bolus or continuous infusion.
Molecular Weight
1302.5 g/mol (kisspeptin-10; molecular formula C63H83N17O14; CAS 374675-21-5)
Administration
Subcutaneous
Trial Phase
Clinical (investigational)
Safety Profile
Common Side Effects
- • Generally well tolerated in short-term clinical studies
- • Possible transient flushing or warmth
- • Mild infusion- or injection-site reactions
- • Headache
- • Short-lived changes in LH/testosterone or, in women, menstrual-cycle timing
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is KSPTN?
KSPTN is vendor shorthand for kisspeptin, a peptide encoded by the KISS1 gene. The research material sold under this code is almost always kisspeptin-10, the active 10-amino-acid fragment (sequence YNWNSFGLRF-NH2, also called metastin 45-54). It is a potent agonist of the kisspeptin receptor KISS1R (GPR54).
What does kisspeptin actually do?
It acts upstream of the reproductive axis. Kisspeptin stimulates GnRH neurons in the hypothalamus, which drives the pituitary to release LH and FSH, which signal the gonads to make testosterone (men) or estrogen and progesterone and to trigger ovulation (women). According to PubMed, an IV dose of kisspeptin-10 potently raises LH and, in men, testosterone in healthy volunteers [PMID:17323132].
Is kisspeptin FDA-approved?
No. Kisspeptin is investigational. It has been studied in numerous human clinical trials - for IVF egg-maturation triggering, hypogonadism, hypothalamic amenorrhea and sexual desire - but it is not an approved drug, and material sold to consumers is labeled research use only.
Can I inject it subcutaneously like other peptides?
There is no validated subcutaneous self-dosing protocol. Every human study of kisspeptin-10 used intravenous administration because the peptide is cleared within minutes. Kisspeptin-54 (a longer form) lasts longer and has been given subcutaneously in IVF trials. Community subcutaneous use of kisspeptin-10 is anecdotal and not supported by pharmacokinetic data.
Will more kisspeptin give a bigger hormonal response?
Not necessarily. The kisspeptin receptor desensitizes with continuous or high-dose exposure, which can blunt the LH response. The natural signal is pulsatile, so overdosing tends to reduce, not amplify, the effect.
How is kisspeptin different from gonadorelin or hCG?
Gonadorelin is GnRH itself, one step further down the axis, and hCG mimics LH directly at the gonad. Kisspeptin acts one step higher, on the GnRH neurons, so it recruits the body's own GnRH pulse generator. In IVF it has been studied as a gentler oocyte-maturation trigger than hCG, with lower ovarian-hyperstimulation risk [PMID:28393578].
What is the difference between kisspeptin-10 and kisspeptin-54?
The KISS1 gene makes a 54-amino-acid peptide (kisspeptin-54, or metastin) that can be cleaved into shorter fragments (kisspeptin-14, -13 and -10) sharing similar receptor potency [PMID:18193176]. Kisspeptin-10 is the short decapeptide most commonly sold as research material; kisspeptin-54 is longer-acting and used in several clinical trials.
Research Tools
Related Compounds
View AllAminotadalafil
OtherPreclinicalAminotadalafil is an unapproved research analog of tadalafil, the PDE5 inhibitor marketed under the brand name Cialis for erectile dysfunction and under Adcirca for pulmonary arterial hypertension.
B7-33
OtherPreclinicalB7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.
Melanotan I
OtherFDA ApprovedMelanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7.
PNC-27
OtherPreclinicalPNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells.
Prostamax
OtherPreclinicalProstamax is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St.
RU-58841
OtherPreclinicalRU-58841 (also known as PSK-3841 or HMR-3841, and commonly written simply as RU in hair-loss forums) is a non-steroidal androgen receptor antagonist originally developed by Roussel Uclaf (later absorbed into Sanofi) in the late 1980s and early 1990s.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.